Novo Nordisk reported DKK203.07B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Bausch Health Companies USD -2.06B 1.5B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Novo Nordisk DKK 26.56B 111.98B Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Sanofi EUR 72.81B 1.1B Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026